Аллергические реакции к компонентам вакцин в обосновании тактики профилактической вакцинации чувствительных пациентов: аналитический обзор
Аллергические реакции к компонентам вакцин в обосновании тактики профилактической вакцинации чувствительных пациентов: аналитический обзор
Для цитирования: Максимова А.В., Смолкин Ю.С. Аллергические реакции к компонентам вакцин в обосновании тактики профилактической вакцинации чувствительных пациентов: аналитический обзор. Педиатрия. Consilium Medicum. 2019; 3: 24–32. DOI: 10.26442/26586630.2019.3.190585
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Вакцинация является одним из самых больших достижений человечества. Вакцины содержат не только иммунизирующий компонент (актуальный антиген), но и балластные вещества, которые используются при производстве вакцинальных препаратов. В данном обзоре представлены основные аллергокомпоненты вакцин, к которым относятся казеин, a-лактальбумин, овальбумин, овомукоид, дрожжи, желатин, латекс, антибактериальные препараты из группы аминогликозидов, формальдегид, полисорбат 80, мертиолят (тиомерсал). Тщательный анализ частоты аллергических реакций при осуществлении вакцинации, проведенный на основании данных последних десятилетий, показал, что вакцинация пациентов, страдающих аллергическими заболеваниями, является не только необходимой, но и безопасной. Отягощенный анамнез по атопии не считается противопоказанием для вакцинации. В случае необходимости возможны проведение предварительного аллергологического обследования на основные компоненты вакцин, а также постановка кожных и внутрикожных тестов непосредственно с вакцинальным препаратом. В случае положительного результата и когда вакцинация признана необходимой, возможно проведение иммунизации согласно протоколу градуированных доз. Персонифицированный подход к проведению процедуры вакцинации, сопоставление данных анамнеза и аллергологического обследования с составом современных вакцинальных препаратов снижают вероятность развития аллергических реакций у сенсибилизированных пациентов.
Ключевые слова: аллергия, вакцинация, дети, обзор, аллергокомпоненты вакцин.
Key words: allergy, vaccination, children, review, the main allergenic molecule of vaccines.
Ключевые слова: аллергия, вакцинация, дети, обзор, аллергокомпоненты вакцин.
________________________________________________
Key words: allergy, vaccination, children, review, the main allergenic molecule of vaccines.
Список литературы
1. Основы вакцинопрофилактики у детей с хронической патологией. Под ред. М.П.Костинова. М.: Медицина для всех, 2002.
[The basics of vaccination in children with chronic pathology. Ed. M.P.Kostinova. Moscow: Meditsina dlia vsekh, 2002 (in Russian).]
2. Larson HJ, De Figueiredo A, Xiahong Z et al. The state of vaccine confidence 2016: global insights through a 67-country survey. EBioMedicine 2016; 12: 295–301.
3. Соловьева И.Л. и др. Напряженность специфического иммунитета у детей с аллергическими заболеваниями при вакцинации против гепатита В. Эпидемиология и вакцинопрофилактика. 2005; 1.
[Solov'eva I.L. et al. Napriazhennost' spetsificheskogo immuniteta u detei s allergicheskimi zabolevaniiami pri vaktsinatsii protiv gepatita V. Epidemiologiia i vaktsinoprofilaktika. 2005; 1 (in Russian).]
4. Магаршак О.О., Костинов М.П. Проблемы вакцинации детей с аллергическими заболеваниями. Лечащий врач. 2008.
[Magarshak O.O., Kostinov M.P. Problemy vaktsinatsii detei s allergicheskimi zabolevaniiami. Lechashchii vrach. 2008 (in Russian).]
5. Immunization Action Coalition. www.immunize-Europe.org
6. Bohlke K et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics 2003; 112 (4): 815–20.
7. American Academy of Pediatrics. Active and passive immunization. L.K.Pickering, ed. Red Book: 2006 Report of the Committee on Infectious Diseases, 28th edn. Elk Grove Village, IL: American Academy of Pediatrics, 2009.
8. Zent O et al. Immediate allergic reactions after vaccinations – a post-marketing surveillance review. Eur J Pediatr 2002; 161 (1): 21–5.
9. McNeil MM et al. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol 2016; 137 (3): 868–78.
10. Hox V et al. Estrogen increases the severity of anaphylaxis in female mice through enhanced endothelial nitric oxide synthase expression and nitric oxide production. J Allergy Clin Immunol 2015; 135 (3): 729–36. e5.
11. Nagao M et al. Highly increased levels of IgE antibodies to vaccine components in children with influenza vaccine – associated anaphylaxis. J Allergy Clin Immunol 2016; 137 (3): 861–7.
12. Sakaguchi M et al. Systemic immediate-type reactions to gelatin included in Japanese encephalitis vaccines. Vaccine 1997; 15 (2): 121–22.
13. Worm M et al. Gelatin-induced urticaria and anaphylaxis after tick-borne encephalitis vaccine. Acta Dermato-venereologica 2000; 80 (3).
14. Kattan JD et al. Anaphylaxis to diphtheria, tetanus, and pertussis vaccines among children with cow’s milk allergy. J Allergy Clin Immunol 2011; 128 (1): 215–18.
15. Vaccines and immunizations. www.cdc.gov/vaccines
16. EAACI Molecular Allergology User´s Guide. Pediatric Allergy and Immunology. Pediatr Allergy Immunol 2016; 27 (Suppl. 23): 1–250.
17. Slater JE, Rabin RL, Martin D. Comments on cow's milk allergy and diphtheria, tetanus, and pertussis vaccines. J Allergy Clin Immunol 2011; 128 (2): 434.
18. McNeil MM et al. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol 2016; 137 (3): 868–78.
19. Nakayama T, Onoda K. Vaccine adverse events reported in post-marketing study of the Kitasato Institute from 1994 to 2004. Vaccine 2007; 25 (3): 570–6.
20. Иммунопрофилактика – 2018. Справочник. 13-е изд., расшир. В.К.Таточенко, Н.А.Озерцовский. М.: Боргес, 2018.
[Immunoprophylaxis – 2018. Spravochnik. 13-e izd., rasshir. V.K.Tatochenko, N.A.Ozertsovskii. Moscow: Borges, 2018 (in Russian).]
21. Beveridge MG et al. Local vaccine site reactions and contact allergy to aluminum. Pediatric Dermatol 2012; 29 (1): 68–72.
22. Bergfors E, Trollfors B. Sixty-four children with persistent itching nodules and contact allergy to aluminium after vaccination with aluminium-adsorbed vaccines – prognosis and outcome after booster vaccination. Eur J Pediatrics 2013; 172 (2): 171–7.
23. Гречуха Т.А. и др. Опыт применения АаКДС-гексавакцины на базе отделения вакцинопрофилактики детей с отклонениями в состоянии здоровья ФГБНУ «Научный центр здоровья детей». Педиатрическая фармакология. 2014; 11 (4).
[Grechukha T.A. et al. Opyt primeneniia AaKDS-geksavaktsiny na baze otdeleniia vaktsinoprofilaktiki detei s otkloneniiami v sostoianii zdorov'ia FGBNU "Nauchnyi tsentr zdorov'ia detei". Pediatricheskaia farmakologiia. 2014; 11 (4) (in Russian).]
24. Parisi CAS et al. Hypersensitivity reactions to the Sabin vaccine in children with cow's milk allergy. Clin Experiment Allergy2013; 43 (2): 249–54.
25. Sakaguchi M, Toda M, Ebihara T et al. IgE antibody to fish gelatin (type I collagen) in patients with fish allergy. J Allergy Clin Immunol 2000; 106 (3): 579–84.
26. Sakaguchi M, Nakayama T, Inouye S. Food allergy to gelatin in children with systemic immediate-type reactions, including anaphylaxis, to vaccines. J Allergy Clin Immunol 1996; 98 (6): 1058–61.
27. Sakai Y et al. Non-antigenic and low allergic gelatin produced by specific digestion with an enzyme-coupled matrix. Biol Pharm Bull 1998; 21 (4): 330–4.
28. Kumagai T et al. Gelatin-specific humoral and cellular immune responses in children with immediate-and nonimmediate-type reactions to live measles, mumps, rubella, and varicella vaccines. J Allergy Clin Immunol 1997; 100 (1): 130–4.
29. Sakaguchi M, Ogura H, Inouye S. IgE antibody to gelatin in children with immediate-type reactions to measles and mumps vaccines. J Allergy Clin Immunol 1995; 96 (4): 563–5.
30. Sakaguchi M et al. Systemic immediate-type reactions to gelatin included in Japanese encephalitis vaccines. Vaccine 1997; 15 (2): 121–2.
31. Worm M et al. Gelatin-induced urticaria and anaphylaxis after tick-borne encephalitis vaccine. Acta Dermato-Venereologica 2000; 80 (3).
32. Kuno-Sakai H, Kimura M. Removal of gelatin from live vaccines and DTaP – an ultimate solution for vaccine-related gelatin allergy. Biologicals 2003; 31 (4): 245–9.
33. Ozaki T et al. Safety and immunogenicity of gelatin-free varicella vaccine in epidemiological and serological studies in Japan. Vaccine 2005; 23 (10): 1205–8.
34. Nagel G, Hennig R, Broeker M. New gelatine-free TBE vaccines with improved safety profile. Klin Padiatr 2006; 218 (6): 379.
35. Nakayama T, Aizawa C. Change in gelatin content of vaccines associated with reduction in reports of allergic reactions. J Allergy Clin Immunol 2000; 106 (3): 591–2.
36. Рубан А.П., Пампура А.Н. Анафилаксия и вакцинация: риски и реалии. Рос. вестн. перинатол. и педиатрии. 2018; 63 (4): 15–22.
[Ruban A.P., Pampura A.N. Anafilaksiia i vaktsinatsiia: riski i realii. Ros. vestn. perinatol. i pediatrii. 2018; 63 (4): 15–22 (in Russian).]
37. Dreskin SC et al. International Consensus (ICON): allergic reactions to vaccines. World Allergy Organization J 2016; 9 (1): 32.
38. Kelso JM. Safety of influenza vaccines. Cur Opin Allergy Clin Immunol 2012; 12 (4): 383–8.
39. Назарова Е.В. Аллергические реакции на вакцины. Эффективная фармакотерапия. 2016; 24: 10–3.
[Nazarova E.V. Allergicheskie reaktsii na vaktsiny. Effektivnaia farmakoterapiia. 2016; 24: 10–3 (in Russian).]
40. Plotkin S. History of vaccination. Proceed National Acad Sci 2014; 111 (34): 12283–7.
41. Majchrowicz H. Post-vaccination reactions to diploid rabies vaccine. Przeglad Epidemiologiczny 1989; 43 (3): 259–62.
42. Xepapadaki P et al. Incidence and natural history of hen's egg allergy in the first 2 years of life – the EuroPrevall birth cohort study. Allergy 2016; 71 (3): 350–7.
43. Panesar SS, Javad S, de Silva D et al on behalf of the EAACI Food Allergy and Anaphylaxis Group. The epidemiology of anaphylaxis in Europe: a systematic review. Allergy 2013; 68: 1353–61.
44. Sicherer SH, Sampson HA. Food allergy: a review and update on epidemiology, pathogenesis, diagnosis, prevention, and management. J Allergy Clin Immunol 2018; 141 (1): 41–58.
45. Пампура А.Н., Варламов Е.Е., Конюкова Н.Г. Пищевая аллергия у детей раннего возраста. Педиатрия. 2016; 95 (3): 152–7.
[Pampura A.N., Varlamov E.E., Koniukova N.G. Pishchevaia allergiia u detei rannego vozrasta. Pediatriia. 2016; 95 (3): 152–7 (in Russian).]
46. Burks AW et al. ICON: food allergy. J Allergy Clin Immunol 2012; 129 (4): 906–20.
47. User guide molecular allergy.
48. Micozzi S, Bartolomé B, Sanchís-Merino ME et al. Hypersensitivity to Quail Egg Proteins: What About Hen Egg? J Invest Allergol Clin Immunol 2016; 26 (5): 316–8.
49. Contreras FJC et al. Allergy to quail's egg without allergy to chicken's egg. Case report. Allergol Immunopathol 2008; 36 (4): 234–7.
50. González-Mancebo E et al. Identification of allergens in chicken meat allergy. J Invest Allergol Clin Immunol 2011; 21 (4): 326–7.
51. McKinney KK et al. Ovalbumin content of 2010-2011 influenza vaccines. J Allergy Clin Immunol 2011; 127 (6): 1629.
52. Halsey NA et al. Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: reports to VAERS. Vaccine 2013; 31 (51): 6107–12.
53. Turner PJ et al. Safety of live attenuated influenza vaccine in young people with egg allergy: multicentre prospective cohort study. BMJ 2015; 351: h6291.
54. Вакцины гриппа – от доклиники до применения. https://www.cmd-online.ru/vracham/nauchnye-dostizheniya/documents/xxxviii-sem/5.pdf
[Vaktsiny grippa – ot dokliniki do primeneniia. https://www.cmd-online.ru/vracham/nauchnye-dostizheniya/documents/xxxviii-sem/5.pdf (in Russian).]
55. Chung EY, Huang L, Schneider L. Safety of influenza vaccine administration in egg-allergic patients. Pediatrics 2010. С. peds. 2009–512.
56. Vaccination of the egg-allergic individual. Australian Society of Clinical Immunology and Allergy 2017. https://allergy.org.au/hp/papers/vaccination-of-the-egg-allergic-individual
57. Flu Vaccine and People with Egg Allergies. Center for Disease Control and Prevention. https://www.cdc.gov/flu/protect/vaccine/egg-allergies.htm
58. Clark AT et al. British Society for Allergy and Clinical Immunology guidelines for the management of egg allergy. Clin Experiment Allergy 2010; 40 (8): 1116–29.
59. Nakayama T, Aizawa C, Kuno-Sakai H. A clinical analysis of gelatin allergy and determination of its causal relationship to the previous administration of gelatin-containing acellular pertussis vaccine combined with diphtheria and tetanus toxoids. J Allergy Clin Immunol 1999; 103 (2): 321–25.
60. Pool V et al. Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps-rubella vaccine in the United States. Pediatrics 2002; 110 (6): e71–e71.
61. Kimberlin DW et al. Red Book (2015): 2015 Report of the Committee on Infectious Diseases. – American academy of pediatrics, 2015; Mumps, Rubella, and Varicella Vaccine. Vaccine Safety. Center for Disease Control and Prevention: https://www.cdc.gov/vaccinesafety/vaccines/mmrv-vaccine.html
62. BSACI Recommendations for Combined Measles, Mumps and Rubella (MMR) Vaccination in Egg-Allergic children 2007; Gilbert T et al. Vaccination in egg-allergic individuals – A local guideline 2017. Hong Kong Institute Allergy 2017; 10: 24–9.
63. DiMiceli L et al. Vaccination of yeast sensitive individuals: review of safety data in the US vaccine adverse event reporting system (VAERS). Vaccine 2006; 24 (6): 703–7.
64. GlaxoSmithKline. ENGERIX-B Package Insert. Mississauga, Ontario, Canada. 2013. Also, http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM224503.pdf
65. Merck & Co. I. RECOMBIVAX HB Package Insert. Merck, Inc. Kenilworth, NJ USA. 2014.Also, https://www.merck.com/product/usa/pi_circulars/r/recombivax_hb/recombivax_pi.pdf66. Merck & Co. I. GARDASIL Package Insert. Merck, Inc. Kenilworth, NJ USA. 2011. Also,http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM111263.pdf
67. Stone Jr CA et al. Immediate Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized. J Allergy Clin Immunol: In Practice 2018.
68. Badiu I et al. Hypersensitivity reaction to human papillomavirus vaccine due to polysorbate 80. BMJ case reports 2012; 2012.
69. Wattanakrai P, Rajatanavin N. Thimerosal allergy and clinical relevance in Thailand. J Med Assoc Thailand 2007; 90 (9): 1775.
70. Lee-Wong M, Resnick D, Chong K. A generalized reaction to thimerosal from an influenza vaccine. Ann Allergy, Asthma Immunol 2005; 94 (1): 90–4.
71. King K, Paterson M, Green SK. Global justice and the proposed ban on thimerosal-containing vaccines. Pediatrics 2013; 131 (1): 154–6.
72. https://www.sovigripp.ru/sovigripp
73. https://www.rlsnet.ru/tn_index_id_3810.htm
74. https://www.rlsnet.ru/tn_index_id_5768.htm
75. https://www.rlsnet.ru/tn_index_id_5759.htm
76. http://allergen.org/search.php?Species=Hevea%20brasiliensis
77. Russell M et al. Vaccination of persons allergic to latex: a review of safety data in the Vaccine Adverse Event Reporting System (VAERS). Vaccine 2004; 23 (5): 664–7.
78. Kelso JM et al. Adverse reactions to vaccines. Ann Allergy, Asthma Immunol 2009; 103 (4): S1–S14.
2. Larson HJ, De Figueiredo A, Xiahong Z et al. The state of vaccine confidence 2016: global insights through a 67-country survey. EBioMedicine 2016; 12: 295–301.
3. Solov'eva I.L. et al. Napriazhennost' spetsificheskogo immuniteta u detei s allergicheskimi zabolevaniiami pri vaktsinatsii protiv gepatita V. Epidemiologiia i vaktsinoprofilaktika. 2005; 1 (in Russian).
4. Magarshak O.O., Kostinov M.P. Problemy vaktsinatsii detei s allergicheskimi zabolevaniiami. Lechashchii vrach. 2008 (in Russian).
5. Immunization Action Coalition. www.immunize-Europe.org
6. Bohlke K et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics 2003; 112 (4): 815–20.
7. American Academy of Pediatrics. Active and passive immunization. L.K.Pickering, ed. Red Book: 2006 Report of the Committee on Infectious Diseases, 28th edn. Elk Grove Village, IL: American Academy of Pediatrics, 2009.
8. Zent O et al. Immediate allergic reactions after vaccinations – a post-marketing surveillance review. Eur J Pediatr 2002; 161 (1): 21–5.
9. McNeil MM et al. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol 2016; 137 (3): 868–78.
10. Hox V et al. Estrogen increases the severity of anaphylaxis in female mice through enhanced endothelial nitric oxide synthase expression and nitric oxide production. J Allergy Clin Immunol 2015; 135 (3): 729–36. e5.
11. Nagao M et al. Highly increased levels of IgE antibodies to vaccine components in children with influenza vaccine – associated anaphylaxis. J Allergy Clin Immunol 2016; 137 (3): 861–7.
12. Sakaguchi M et al. Systemic immediate-type reactions to gelatin included in Japanese encephalitis vaccines. Vaccine 1997; 15 (2): 121–22.
13. Worm M et al. Gelatin-induced urticaria and anaphylaxis after tick-borne encephalitis vaccine. Acta Dermato-venereologica 2000; 80 (3).
14. Kattan JD et al. Anaphylaxis to diphtheria, tetanus, and pertussis vaccines among children with cow’s milk allergy. J Allergy Clin Immunol 2011; 128 (1): 215–18.
15. Vaccines and immunizations. www.cdc.gov/vaccines
16. EAACI Molecular Allergology User´s Guide. Pediatric Allergy and Immunology. Pediatr Allergy Immunol 2016; 27 (Suppl. 23): 1–250.
17. Slater JE, Rabin RL, Martin D. Comments on cow's milk allergy and diphtheria, tetanus, and pertussis vaccines. J Allergy Clin Immunol 2011; 128 (2): 434.
18. McNeil MM et al. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol 2016; 137 (3): 868–78.
19. Nakayama T, Onoda K. Vaccine adverse events reported in post-marketing study of the Kitasato Institute from 1994 to 2004. Vaccine 2007; 25 (3): 570–6.
20. Immunoprophylaxis – 2018. Spravochnik. 13-e izd., rasshir. V.K.Tatochenko, N.A.Ozertsovskii. Moscow: Borges, 2018 (in Russian).
21. Beveridge MG et al. Local vaccine site reactions and contact allergy to aluminum. Pediatric Dermatol 2012; 29 (1): 68–72.
22. Bergfors E, Trollfors B. Sixty-four children with persistent itching nodules and contact allergy to aluminium after vaccination with aluminium-adsorbed vaccines – prognosis and outcome after booster vaccination. Eur J Pediatrics 2013; 172 (2): 171–7.
23. Grechukha T.A. et al. Opyt primeneniia AaKDS-geksavaktsiny na baze otdeleniia vaktsinoprofilaktiki detei s otkloneniiami v sostoianii zdorov'ia FGBNU "Nauchnyi tsentr zdorov'ia detei". Pediatricheskaia farmakologiia. 2014; 11 (4) (in Russian).
24. Parisi CAS et al. Hypersensitivity reactions to the Sabin vaccine in children with cow's milk allergy. Clin Experiment Allergy2013; 43 (2): 249–54.
25. Sakaguchi M, Toda M, Ebihara T et al. IgE antibody to fish gelatin (type I collagen) in patients with fish allergy. J Allergy Clin Immunol 2000; 106 (3): 579–84.
26. Sakaguchi M, Nakayama T, Inouye S. Food allergy to gelatin in children with systemic immediate-type reactions, including anaphylaxis, to vaccines. J Allergy Clin Immunol 1996; 98 (6): 1058–61.
27. Sakai Y et al. Non-antigenic and low allergic gelatin produced by specific digestion with an enzyme-coupled matrix. Biol Pharm Bull 1998; 21 (4): 330–4.
28. Kumagai T et al. Gelatin-specific humoral and cellular immune responses in children with immediate-and nonimmediate-type reactions to live measles, mumps, rubella, and varicella vaccines. J Allergy Clin Immunol 1997; 100 (1): 130–4.
29. Sakaguchi M, Ogura H, Inouye S. IgE antibody to gelatin in children with immediate-type reactions to measles and mumps vaccines. J Allergy Clin Immunol 1995; 96 (4): 563–5.
30. Sakaguchi M et al. Systemic immediate-type reactions to gelatin included in Japanese encephalitis vaccines. Vaccine 1997; 15 (2): 121–2.
31. Worm M et al. Gelatin-induced urticaria and anaphylaxis after tick-borne encephalitis vaccine. Acta Dermato-Venereologica 2000; 80 (3).
32. Kuno-Sakai H, Kimura M. Removal of gelatin from live vaccines and DTaP – an ultimate solution for vaccine-related gelatin allergy. Biologicals 2003; 31 (4): 245–9.
33. Ozaki T et al. Safety and immunogenicity of gelatin-free varicella vaccine in epidemiological and serological studies in Japan. Vaccine 2005; 23 (10): 1205–8.
34. Nagel G, Hennig R, Broeker M. New gelatine-free TBE vaccines with improved safety profile. Klin Padiatr 2006; 218 (6): 379.
35. Nakayama T, Aizawa C. Change in gelatin content of vaccines associated with reduction in reports of allergic reactions. J Allergy Clin Immunol 2000; 106 (3): 591–2.
36. Рубан А.П., Пампура А.Н. Анафилаксия и вакцинация: риски и реалии. Рос. вестн. перинатол. и педиатрии. 2018; 63 (4): 15–22.
[Ruban A.P., Pampura A.N. Anafilaksiia i vaktsinatsiia: riski i realii. Ros. vestn. perinatol. i pediatrii. 2018; 63 (4): 15–22 (in Russian).]
37. Dreskin SC et al. International Consensus (ICON): allergic reactions to vaccines. World Allergy Organization J 2016; 9 (1): 32.
38. Kelso JM. Safety of influenza vaccines. Cur Opin Allergy Clin Immunol 2012; 12 (4): 383–8.
39. Nazarova E.V. Allergicheskie reaktsii na vaktsiny. Effektivnaia farmakoterapiia. 2016; 24: 10–3 (in Russian).
40. Plotkin S. History of vaccination. Proceed National Acad Sci 2014; 111 (34): 12283–7.
41. Majchrowicz H. Post-vaccination reactions to diploid rabies vaccine. Przeglad Epidemiologiczny 1989; 43 (3): 259–62.
42. Xepapadaki P et al. Incidence and natural history of hen's egg allergy in the first 2 years of life – the EuroPrevall birth cohort study. Allergy 2016; 71 (3): 350–7.
43. Panesar SS, Javad S, de Silva D et al on behalf of the EAACI Food Allergy and Anaphylaxis Group. The epidemiology of anaphylaxis in Europe: a systematic review. Allergy 2013; 68: 1353–61.
44. Sicherer SH, Sampson HA. Food allergy: a review and update on epidemiology, pathogenesis, diagnosis, prevention, and management. J Allergy Clin Immunol 2018; 141 (1): 41–58.
45. Pampura A.N., Varlamov E.E., Koniukova N.G. Pishchevaia allergiia u detei rannego vozrasta. Pediatriia. 2016; 95 (3): 152–7 (in Russian).
46. Burks AW et al. ICON: food allergy. J Allergy Clin Immunol 2012; 129 (4): 906–20.
47. User guide molecular allergy.
48. Micozzi S, Bartolomé B, Sanchís-Merino ME et al. Hypersensitivity to Quail Egg Proteins: What About Hen Egg? J Invest Allergol Clin Immunol 2016; 26 (5): 316–8.
49. Contreras FJC et al. Allergy to quail's egg without allergy to chicken's egg. Case report. Allergol Immunopathol 2008; 36 (4): 234–7.
50. González-Mancebo E et al. Identification of allergens in chicken meat allergy. J Invest Allergol Clin Immunol 2011; 21 (4): 326–7.
51. McKinney KK et al. Ovalbumin content of 2010-2011 influenza vaccines. J Allergy Clin Immunol 2011; 127 (6): 1629.
52. Halsey NA et al. Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: reports to VAERS. Vaccine 2013; 31 (51): 6107–12.
53. Turner PJ et al. Safety of live attenuated influenza vaccine in young people with egg allergy: multicentre prospective cohort study. BMJ 2015; 351: h6291.
54. Vaktsiny grippa – ot dokliniki do primeneniia. https://www.cmd-online.ru/vracham/nauchnye-dostizheniya/documents/xxxviii-sem/5.pdf (in Russian).
55. Chung EY, Huang L, Schneider L. Safety of influenza vaccine administration in egg-allergic patients. Pediatrics 2010. С. peds. 2009–512.
56. Vaccination of the egg-allergic individual. Australian Society of Clinical Immunology and Allergy 2017. https://allergy.org.au/hp/papers/vaccination-of-the-egg-allergic-individual
57. Flu Vaccine and People with Egg Allergies. Center for Disease Control and Prevention. https://www.cdc.gov/flu/protect/vaccine/egg-allergies.htm
58. Clark AT et al. British Society for Allergy and Clinical Immunology guidelines for the management of egg allergy. Clin Experiment Allergy 2010; 40 (8): 1116–29.
59. Nakayama T, Aizawa C, Kuno-Sakai H. A clinical analysis of gelatin allergy and determination of its causal relationship to the previous administration of gelatin-containing acellular pertussis vaccine combined with diphtheria and tetanus toxoids. J Allergy Clin Immunol 1999; 103 (2): 321–25.
60. Pool V et al. Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps-rubella vaccine in the United States. Pediatrics 2002; 110 (6): e71–e71.
61. Kimberlin DW et al. Red Book (2015): 2015 Report of the Committee on Infectious Diseases. – American academy of pediatrics, 2015; Mumps, Rubella, and Varicella Vaccine. Vaccine Safety. Center for Disease Control and Prevention: https://www.cdc.gov/vaccinesafety/vaccines/mmrv-vaccine.html
62. BSACI Recommendations for Combined Measles, Mumps and Rubella (MMR) Vaccination in Egg-Allergic children 2007; Gilbert T et al. Vaccination in egg-allergic individuals – A local guideline 2017. Hong Kong Institute Allergy 2017; 10: 24–9.
63. DiMiceli L et al. Vaccination of yeast sensitive individuals: review of safety data in the US vaccine adverse event reporting system (VAERS). Vaccine 2006; 24 (6): 703–7.
64. GlaxoSmithKline. ENGERIX-B Package Insert. Mississauga, Ontario, Canada. 2013. Also, http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM224503.pdf
65. Merck & Co. I. RECOMBIVAX HB Package Insert. Merck, Inc. Kenilworth, NJ USA. 2014.Also, https://www.merck.com/product/usa/pi_circulars/r/recombivax_hb/recombivax_pi.pdf66. Merck & Co. I. GARDASIL Package Insert. Merck, Inc. Kenilworth, NJ USA. 2011. Also,http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM111263.pdf
67. Stone Jr CA et al. Immediate Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized. J Allergy Clin Immunol: In Practice 2018.
68. Badiu I et al. Hypersensitivity reaction to human papillomavirus vaccine due to polysorbate 80. BMJ case reports 2012; 2012.
69. Wattanakrai P, Rajatanavin N. Thimerosal allergy and clinical relevance in Thailand. J Med Assoc Thailand 2007; 90 (9): 1775.
70. Lee-Wong M, Resnick D, Chong K. A generalized reaction to thimerosal from an influenza vaccine. Ann Allergy, Asthma Immunol 2005; 94 (1): 90–4.
71. King K, Paterson M, Green SK. Global justice and the proposed ban on thimerosal-containing vaccines. Pediatrics 2013; 131 (1): 154–6.
72. https://www.sovigripp.ru/sovigripp
73. https://www.rlsnet.ru/tn_index_id_3810.htm
74. https://www.rlsnet.ru/tn_index_id_5768.htm
75. https://www.rlsnet.ru/tn_index_id_5759.htm
76. http://allergen.org/search.php?Species=Hevea%20brasiliensis
77. Russell M et al. Vaccination of persons allergic to latex: a review of safety data in the Vaccine Adverse Event Reporting System (VAERS). Vaccine 2004; 23 (5): 664–7.
78. Kelso JM et al. Adverse reactions to vaccines. Ann Allergy, Asthma Immunol 2009; 103 (4): S1–S14.
[The basics of vaccination in children with chronic pathology. Ed. M.P.Kostinova. Moscow: Meditsina dlia vsekh, 2002 (in Russian).]
2. Larson HJ, De Figueiredo A, Xiahong Z et al. The state of vaccine confidence 2016: global insights through a 67-country survey. EBioMedicine 2016; 12: 295–301.
3. Соловьева И.Л. и др. Напряженность специфического иммунитета у детей с аллергическими заболеваниями при вакцинации против гепатита В. Эпидемиология и вакцинопрофилактика. 2005; 1.
[Solov'eva I.L. et al. Napriazhennost' spetsificheskogo immuniteta u detei s allergicheskimi zabolevaniiami pri vaktsinatsii protiv gepatita V. Epidemiologiia i vaktsinoprofilaktika. 2005; 1 (in Russian).]
4. Магаршак О.О., Костинов М.П. Проблемы вакцинации детей с аллергическими заболеваниями. Лечащий врач. 2008.
[Magarshak O.O., Kostinov M.P. Problemy vaktsinatsii detei s allergicheskimi zabolevaniiami. Lechashchii vrach. 2008 (in Russian).]
5. Immunization Action Coalition. www.immunize-Europe.org
6. Bohlke K et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics 2003; 112 (4): 815–20.
7. American Academy of Pediatrics. Active and passive immunization. L.K.Pickering, ed. Red Book: 2006 Report of the Committee on Infectious Diseases, 28th edn. Elk Grove Village, IL: American Academy of Pediatrics, 2009.
8. Zent O et al. Immediate allergic reactions after vaccinations – a post-marketing surveillance review. Eur J Pediatr 2002; 161 (1): 21–5.
9. McNeil MM et al. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol 2016; 137 (3): 868–78.
10. Hox V et al. Estrogen increases the severity of anaphylaxis in female mice through enhanced endothelial nitric oxide synthase expression and nitric oxide production. J Allergy Clin Immunol 2015; 135 (3): 729–36. e5.
11. Nagao M et al. Highly increased levels of IgE antibodies to vaccine components in children with influenza vaccine – associated anaphylaxis. J Allergy Clin Immunol 2016; 137 (3): 861–7.
12. Sakaguchi M et al. Systemic immediate-type reactions to gelatin included in Japanese encephalitis vaccines. Vaccine 1997; 15 (2): 121–22.
13. Worm M et al. Gelatin-induced urticaria and anaphylaxis after tick-borne encephalitis vaccine. Acta Dermato-venereologica 2000; 80 (3).
14. Kattan JD et al. Anaphylaxis to diphtheria, tetanus, and pertussis vaccines among children with cow’s milk allergy. J Allergy Clin Immunol 2011; 128 (1): 215–18.
15. Vaccines and immunizations. www.cdc.gov/vaccines
16. EAACI Molecular Allergology User´s Guide. Pediatric Allergy and Immunology. Pediatr Allergy Immunol 2016; 27 (Suppl. 23): 1–250.
17. Slater JE, Rabin RL, Martin D. Comments on cow's milk allergy and diphtheria, tetanus, and pertussis vaccines. J Allergy Clin Immunol 2011; 128 (2): 434.
18. McNeil MM et al. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol 2016; 137 (3): 868–78.
19. Nakayama T, Onoda K. Vaccine adverse events reported in post-marketing study of the Kitasato Institute from 1994 to 2004. Vaccine 2007; 25 (3): 570–6.
20. Иммунопрофилактика – 2018. Справочник. 13-е изд., расшир. В.К.Таточенко, Н.А.Озерцовский. М.: Боргес, 2018.
[Immunoprophylaxis – 2018. Spravochnik. 13-e izd., rasshir. V.K.Tatochenko, N.A.Ozertsovskii. Moscow: Borges, 2018 (in Russian).]
21. Beveridge MG et al. Local vaccine site reactions and contact allergy to aluminum. Pediatric Dermatol 2012; 29 (1): 68–72.
22. Bergfors E, Trollfors B. Sixty-four children with persistent itching nodules and contact allergy to aluminium after vaccination with aluminium-adsorbed vaccines – prognosis and outcome after booster vaccination. Eur J Pediatrics 2013; 172 (2): 171–7.
23. Гречуха Т.А. и др. Опыт применения АаКДС-гексавакцины на базе отделения вакцинопрофилактики детей с отклонениями в состоянии здоровья ФГБНУ «Научный центр здоровья детей». Педиатрическая фармакология. 2014; 11 (4).
[Grechukha T.A. et al. Opyt primeneniia AaKDS-geksavaktsiny na baze otdeleniia vaktsinoprofilaktiki detei s otkloneniiami v sostoianii zdorov'ia FGBNU "Nauchnyi tsentr zdorov'ia detei". Pediatricheskaia farmakologiia. 2014; 11 (4) (in Russian).]
24. Parisi CAS et al. Hypersensitivity reactions to the Sabin vaccine in children with cow's milk allergy. Clin Experiment Allergy2013; 43 (2): 249–54.
25. Sakaguchi M, Toda M, Ebihara T et al. IgE antibody to fish gelatin (type I collagen) in patients with fish allergy. J Allergy Clin Immunol 2000; 106 (3): 579–84.
26. Sakaguchi M, Nakayama T, Inouye S. Food allergy to gelatin in children with systemic immediate-type reactions, including anaphylaxis, to vaccines. J Allergy Clin Immunol 1996; 98 (6): 1058–61.
27. Sakai Y et al. Non-antigenic and low allergic gelatin produced by specific digestion with an enzyme-coupled matrix. Biol Pharm Bull 1998; 21 (4): 330–4.
28. Kumagai T et al. Gelatin-specific humoral and cellular immune responses in children with immediate-and nonimmediate-type reactions to live measles, mumps, rubella, and varicella vaccines. J Allergy Clin Immunol 1997; 100 (1): 130–4.
29. Sakaguchi M, Ogura H, Inouye S. IgE antibody to gelatin in children with immediate-type reactions to measles and mumps vaccines. J Allergy Clin Immunol 1995; 96 (4): 563–5.
30. Sakaguchi M et al. Systemic immediate-type reactions to gelatin included in Japanese encephalitis vaccines. Vaccine 1997; 15 (2): 121–2.
31. Worm M et al. Gelatin-induced urticaria and anaphylaxis after tick-borne encephalitis vaccine. Acta Dermato-Venereologica 2000; 80 (3).
32. Kuno-Sakai H, Kimura M. Removal of gelatin from live vaccines and DTaP – an ultimate solution for vaccine-related gelatin allergy. Biologicals 2003; 31 (4): 245–9.
33. Ozaki T et al. Safety and immunogenicity of gelatin-free varicella vaccine in epidemiological and serological studies in Japan. Vaccine 2005; 23 (10): 1205–8.
34. Nagel G, Hennig R, Broeker M. New gelatine-free TBE vaccines with improved safety profile. Klin Padiatr 2006; 218 (6): 379.
35. Nakayama T, Aizawa C. Change in gelatin content of vaccines associated with reduction in reports of allergic reactions. J Allergy Clin Immunol 2000; 106 (3): 591–2.
36. Рубан А.П., Пампура А.Н. Анафилаксия и вакцинация: риски и реалии. Рос. вестн. перинатол. и педиатрии. 2018; 63 (4): 15–22.
[Ruban A.P., Pampura A.N. Anafilaksiia i vaktsinatsiia: riski i realii. Ros. vestn. perinatol. i pediatrii. 2018; 63 (4): 15–22 (in Russian).]
37. Dreskin SC et al. International Consensus (ICON): allergic reactions to vaccines. World Allergy Organization J 2016; 9 (1): 32.
38. Kelso JM. Safety of influenza vaccines. Cur Opin Allergy Clin Immunol 2012; 12 (4): 383–8.
39. Назарова Е.В. Аллергические реакции на вакцины. Эффективная фармакотерапия. 2016; 24: 10–3.
[Nazarova E.V. Allergicheskie reaktsii na vaktsiny. Effektivnaia farmakoterapiia. 2016; 24: 10–3 (in Russian).]
40. Plotkin S. History of vaccination. Proceed National Acad Sci 2014; 111 (34): 12283–7.
41. Majchrowicz H. Post-vaccination reactions to diploid rabies vaccine. Przeglad Epidemiologiczny 1989; 43 (3): 259–62.
42. Xepapadaki P et al. Incidence and natural history of hen's egg allergy in the first 2 years of life – the EuroPrevall birth cohort study. Allergy 2016; 71 (3): 350–7.
43. Panesar SS, Javad S, de Silva D et al on behalf of the EAACI Food Allergy and Anaphylaxis Group. The epidemiology of anaphylaxis in Europe: a systematic review. Allergy 2013; 68: 1353–61.
44. Sicherer SH, Sampson HA. Food allergy: a review and update on epidemiology, pathogenesis, diagnosis, prevention, and management. J Allergy Clin Immunol 2018; 141 (1): 41–58.
45. Пампура А.Н., Варламов Е.Е., Конюкова Н.Г. Пищевая аллергия у детей раннего возраста. Педиатрия. 2016; 95 (3): 152–7.
[Pampura A.N., Varlamov E.E., Koniukova N.G. Pishchevaia allergiia u detei rannego vozrasta. Pediatriia. 2016; 95 (3): 152–7 (in Russian).]
46. Burks AW et al. ICON: food allergy. J Allergy Clin Immunol 2012; 129 (4): 906–20.
47. User guide molecular allergy.
48. Micozzi S, Bartolomé B, Sanchís-Merino ME et al. Hypersensitivity to Quail Egg Proteins: What About Hen Egg? J Invest Allergol Clin Immunol 2016; 26 (5): 316–8.
49. Contreras FJC et al. Allergy to quail's egg without allergy to chicken's egg. Case report. Allergol Immunopathol 2008; 36 (4): 234–7.
50. González-Mancebo E et al. Identification of allergens in chicken meat allergy. J Invest Allergol Clin Immunol 2011; 21 (4): 326–7.
51. McKinney KK et al. Ovalbumin content of 2010-2011 influenza vaccines. J Allergy Clin Immunol 2011; 127 (6): 1629.
52. Halsey NA et al. Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: reports to VAERS. Vaccine 2013; 31 (51): 6107–12.
53. Turner PJ et al. Safety of live attenuated influenza vaccine in young people with egg allergy: multicentre prospective cohort study. BMJ 2015; 351: h6291.
54. Вакцины гриппа – от доклиники до применения. https://www.cmd-online.ru/vracham/nauchnye-dostizheniya/documents/xxxviii-sem/5.pdf
[Vaktsiny grippa – ot dokliniki do primeneniia. https://www.cmd-online.ru/vracham/nauchnye-dostizheniya/documents/xxxviii-sem/5.pdf (in Russian).]
55. Chung EY, Huang L, Schneider L. Safety of influenza vaccine administration in egg-allergic patients. Pediatrics 2010. С. peds. 2009–512.
56. Vaccination of the egg-allergic individual. Australian Society of Clinical Immunology and Allergy 2017. https://allergy.org.au/hp/papers/vaccination-of-the-egg-allergic-individual
57. Flu Vaccine and People with Egg Allergies. Center for Disease Control and Prevention. https://www.cdc.gov/flu/protect/vaccine/egg-allergies.htm
58. Clark AT et al. British Society for Allergy and Clinical Immunology guidelines for the management of egg allergy. Clin Experiment Allergy 2010; 40 (8): 1116–29.
59. Nakayama T, Aizawa C, Kuno-Sakai H. A clinical analysis of gelatin allergy and determination of its causal relationship to the previous administration of gelatin-containing acellular pertussis vaccine combined with diphtheria and tetanus toxoids. J Allergy Clin Immunol 1999; 103 (2): 321–25.
60. Pool V et al. Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps-rubella vaccine in the United States. Pediatrics 2002; 110 (6): e71–e71.
61. Kimberlin DW et al. Red Book (2015): 2015 Report of the Committee on Infectious Diseases. – American academy of pediatrics, 2015; Mumps, Rubella, and Varicella Vaccine. Vaccine Safety. Center for Disease Control and Prevention: https://www.cdc.gov/vaccinesafety/vaccines/mmrv-vaccine.html
62. BSACI Recommendations for Combined Measles, Mumps and Rubella (MMR) Vaccination in Egg-Allergic children 2007; Gilbert T et al. Vaccination in egg-allergic individuals – A local guideline 2017. Hong Kong Institute Allergy 2017; 10: 24–9.
63. DiMiceli L et al. Vaccination of yeast sensitive individuals: review of safety data in the US vaccine adverse event reporting system (VAERS). Vaccine 2006; 24 (6): 703–7.
64. GlaxoSmithKline. ENGERIX-B Package Insert. Mississauga, Ontario, Canada. 2013. Also, http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM224503.pdf
65. Merck & Co. I. RECOMBIVAX HB Package Insert. Merck, Inc. Kenilworth, NJ USA. 2014.Also, https://www.merck.com/product/usa/pi_circulars/r/recombivax_hb/recombivax_pi.pdf66. Merck & Co. I. GARDASIL Package Insert. Merck, Inc. Kenilworth, NJ USA. 2011. Also,http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM111263.pdf
67. Stone Jr CA et al. Immediate Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized. J Allergy Clin Immunol: In Practice 2018.
68. Badiu I et al. Hypersensitivity reaction to human papillomavirus vaccine due to polysorbate 80. BMJ case reports 2012; 2012.
69. Wattanakrai P, Rajatanavin N. Thimerosal allergy and clinical relevance in Thailand. J Med Assoc Thailand 2007; 90 (9): 1775.
70. Lee-Wong M, Resnick D, Chong K. A generalized reaction to thimerosal from an influenza vaccine. Ann Allergy, Asthma Immunol 2005; 94 (1): 90–4.
71. King K, Paterson M, Green SK. Global justice and the proposed ban on thimerosal-containing vaccines. Pediatrics 2013; 131 (1): 154–6.
72. https://www.sovigripp.ru/sovigripp
73. https://www.rlsnet.ru/tn_index_id_3810.htm
74. https://www.rlsnet.ru/tn_index_id_5768.htm
75. https://www.rlsnet.ru/tn_index_id_5759.htm
76. http://allergen.org/search.php?Species=Hevea%20brasiliensis
77. Russell M et al. Vaccination of persons allergic to latex: a review of safety data in the Vaccine Adverse Event Reporting System (VAERS). Vaccine 2004; 23 (5): 664–7.
78. Kelso JM et al. Adverse reactions to vaccines. Ann Allergy, Asthma Immunol 2009; 103 (4): S1–S14.
________________________________________________
2. Larson HJ, De Figueiredo A, Xiahong Z et al. The state of vaccine confidence 2016: global insights through a 67-country survey. EBioMedicine 2016; 12: 295–301.
3. Solov'eva I.L. et al. Napriazhennost' spetsificheskogo immuniteta u detei s allergicheskimi zabolevaniiami pri vaktsinatsii protiv gepatita V. Epidemiologiia i vaktsinoprofilaktika. 2005; 1 (in Russian).
4. Magarshak O.O., Kostinov M.P. Problemy vaktsinatsii detei s allergicheskimi zabolevaniiami. Lechashchii vrach. 2008 (in Russian).
5. Immunization Action Coalition. www.immunize-Europe.org
6. Bohlke K et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics 2003; 112 (4): 815–20.
7. American Academy of Pediatrics. Active and passive immunization. L.K.Pickering, ed. Red Book: 2006 Report of the Committee on Infectious Diseases, 28th edn. Elk Grove Village, IL: American Academy of Pediatrics, 2009.
8. Zent O et al. Immediate allergic reactions after vaccinations – a post-marketing surveillance review. Eur J Pediatr 2002; 161 (1): 21–5.
9. McNeil MM et al. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol 2016; 137 (3): 868–78.
10. Hox V et al. Estrogen increases the severity of anaphylaxis in female mice through enhanced endothelial nitric oxide synthase expression and nitric oxide production. J Allergy Clin Immunol 2015; 135 (3): 729–36. e5.
11. Nagao M et al. Highly increased levels of IgE antibodies to vaccine components in children with influenza vaccine – associated anaphylaxis. J Allergy Clin Immunol 2016; 137 (3): 861–7.
12. Sakaguchi M et al. Systemic immediate-type reactions to gelatin included in Japanese encephalitis vaccines. Vaccine 1997; 15 (2): 121–22.
13. Worm M et al. Gelatin-induced urticaria and anaphylaxis after tick-borne encephalitis vaccine. Acta Dermato-venereologica 2000; 80 (3).
14. Kattan JD et al. Anaphylaxis to diphtheria, tetanus, and pertussis vaccines among children with cow’s milk allergy. J Allergy Clin Immunol 2011; 128 (1): 215–18.
15. Vaccines and immunizations. www.cdc.gov/vaccines
16. EAACI Molecular Allergology User´s Guide. Pediatric Allergy and Immunology. Pediatr Allergy Immunol 2016; 27 (Suppl. 23): 1–250.
17. Slater JE, Rabin RL, Martin D. Comments on cow's milk allergy and diphtheria, tetanus, and pertussis vaccines. J Allergy Clin Immunol 2011; 128 (2): 434.
18. McNeil MM et al. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol 2016; 137 (3): 868–78.
19. Nakayama T, Onoda K. Vaccine adverse events reported in post-marketing study of the Kitasato Institute from 1994 to 2004. Vaccine 2007; 25 (3): 570–6.
20. Immunoprophylaxis – 2018. Spravochnik. 13-e izd., rasshir. V.K.Tatochenko, N.A.Ozertsovskii. Moscow: Borges, 2018 (in Russian).
21. Beveridge MG et al. Local vaccine site reactions and contact allergy to aluminum. Pediatric Dermatol 2012; 29 (1): 68–72.
22. Bergfors E, Trollfors B. Sixty-four children with persistent itching nodules and contact allergy to aluminium after vaccination with aluminium-adsorbed vaccines – prognosis and outcome after booster vaccination. Eur J Pediatrics 2013; 172 (2): 171–7.
23. Grechukha T.A. et al. Opyt primeneniia AaKDS-geksavaktsiny na baze otdeleniia vaktsinoprofilaktiki detei s otkloneniiami v sostoianii zdorov'ia FGBNU "Nauchnyi tsentr zdorov'ia detei". Pediatricheskaia farmakologiia. 2014; 11 (4) (in Russian).
24. Parisi CAS et al. Hypersensitivity reactions to the Sabin vaccine in children with cow's milk allergy. Clin Experiment Allergy2013; 43 (2): 249–54.
25. Sakaguchi M, Toda M, Ebihara T et al. IgE antibody to fish gelatin (type I collagen) in patients with fish allergy. J Allergy Clin Immunol 2000; 106 (3): 579–84.
26. Sakaguchi M, Nakayama T, Inouye S. Food allergy to gelatin in children with systemic immediate-type reactions, including anaphylaxis, to vaccines. J Allergy Clin Immunol 1996; 98 (6): 1058–61.
27. Sakai Y et al. Non-antigenic and low allergic gelatin produced by specific digestion with an enzyme-coupled matrix. Biol Pharm Bull 1998; 21 (4): 330–4.
28. Kumagai T et al. Gelatin-specific humoral and cellular immune responses in children with immediate-and nonimmediate-type reactions to live measles, mumps, rubella, and varicella vaccines. J Allergy Clin Immunol 1997; 100 (1): 130–4.
29. Sakaguchi M, Ogura H, Inouye S. IgE antibody to gelatin in children with immediate-type reactions to measles and mumps vaccines. J Allergy Clin Immunol 1995; 96 (4): 563–5.
30. Sakaguchi M et al. Systemic immediate-type reactions to gelatin included in Japanese encephalitis vaccines. Vaccine 1997; 15 (2): 121–2.
31. Worm M et al. Gelatin-induced urticaria and anaphylaxis after tick-borne encephalitis vaccine. Acta Dermato-Venereologica 2000; 80 (3).
32. Kuno-Sakai H, Kimura M. Removal of gelatin from live vaccines and DTaP – an ultimate solution for vaccine-related gelatin allergy. Biologicals 2003; 31 (4): 245–9.
33. Ozaki T et al. Safety and immunogenicity of gelatin-free varicella vaccine in epidemiological and serological studies in Japan. Vaccine 2005; 23 (10): 1205–8.
34. Nagel G, Hennig R, Broeker M. New gelatine-free TBE vaccines with improved safety profile. Klin Padiatr 2006; 218 (6): 379.
35. Nakayama T, Aizawa C. Change in gelatin content of vaccines associated with reduction in reports of allergic reactions. J Allergy Clin Immunol 2000; 106 (3): 591–2.
36. Рубан А.П., Пампура А.Н. Анафилаксия и вакцинация: риски и реалии. Рос. вестн. перинатол. и педиатрии. 2018; 63 (4): 15–22.
[Ruban A.P., Pampura A.N. Anafilaksiia i vaktsinatsiia: riski i realii. Ros. vestn. perinatol. i pediatrii. 2018; 63 (4): 15–22 (in Russian).]
37. Dreskin SC et al. International Consensus (ICON): allergic reactions to vaccines. World Allergy Organization J 2016; 9 (1): 32.
38. Kelso JM. Safety of influenza vaccines. Cur Opin Allergy Clin Immunol 2012; 12 (4): 383–8.
39. Nazarova E.V. Allergicheskie reaktsii na vaktsiny. Effektivnaia farmakoterapiia. 2016; 24: 10–3 (in Russian).
40. Plotkin S. History of vaccination. Proceed National Acad Sci 2014; 111 (34): 12283–7.
41. Majchrowicz H. Post-vaccination reactions to diploid rabies vaccine. Przeglad Epidemiologiczny 1989; 43 (3): 259–62.
42. Xepapadaki P et al. Incidence and natural history of hen's egg allergy in the first 2 years of life – the EuroPrevall birth cohort study. Allergy 2016; 71 (3): 350–7.
43. Panesar SS, Javad S, de Silva D et al on behalf of the EAACI Food Allergy and Anaphylaxis Group. The epidemiology of anaphylaxis in Europe: a systematic review. Allergy 2013; 68: 1353–61.
44. Sicherer SH, Sampson HA. Food allergy: a review and update on epidemiology, pathogenesis, diagnosis, prevention, and management. J Allergy Clin Immunol 2018; 141 (1): 41–58.
45. Pampura A.N., Varlamov E.E., Koniukova N.G. Pishchevaia allergiia u detei rannego vozrasta. Pediatriia. 2016; 95 (3): 152–7 (in Russian).
46. Burks AW et al. ICON: food allergy. J Allergy Clin Immunol 2012; 129 (4): 906–20.
47. User guide molecular allergy.
48. Micozzi S, Bartolomé B, Sanchís-Merino ME et al. Hypersensitivity to Quail Egg Proteins: What About Hen Egg? J Invest Allergol Clin Immunol 2016; 26 (5): 316–8.
49. Contreras FJC et al. Allergy to quail's egg without allergy to chicken's egg. Case report. Allergol Immunopathol 2008; 36 (4): 234–7.
50. González-Mancebo E et al. Identification of allergens in chicken meat allergy. J Invest Allergol Clin Immunol 2011; 21 (4): 326–7.
51. McKinney KK et al. Ovalbumin content of 2010-2011 influenza vaccines. J Allergy Clin Immunol 2011; 127 (6): 1629.
52. Halsey NA et al. Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: reports to VAERS. Vaccine 2013; 31 (51): 6107–12.
53. Turner PJ et al. Safety of live attenuated influenza vaccine in young people with egg allergy: multicentre prospective cohort study. BMJ 2015; 351: h6291.
54. Vaktsiny grippa – ot dokliniki do primeneniia. https://www.cmd-online.ru/vracham/nauchnye-dostizheniya/documents/xxxviii-sem/5.pdf (in Russian).
55. Chung EY, Huang L, Schneider L. Safety of influenza vaccine administration in egg-allergic patients. Pediatrics 2010. С. peds. 2009–512.
56. Vaccination of the egg-allergic individual. Australian Society of Clinical Immunology and Allergy 2017. https://allergy.org.au/hp/papers/vaccination-of-the-egg-allergic-individual
57. Flu Vaccine and People with Egg Allergies. Center for Disease Control and Prevention. https://www.cdc.gov/flu/protect/vaccine/egg-allergies.htm
58. Clark AT et al. British Society for Allergy and Clinical Immunology guidelines for the management of egg allergy. Clin Experiment Allergy 2010; 40 (8): 1116–29.
59. Nakayama T, Aizawa C, Kuno-Sakai H. A clinical analysis of gelatin allergy and determination of its causal relationship to the previous administration of gelatin-containing acellular pertussis vaccine combined with diphtheria and tetanus toxoids. J Allergy Clin Immunol 1999; 103 (2): 321–25.
60. Pool V et al. Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps-rubella vaccine in the United States. Pediatrics 2002; 110 (6): e71–e71.
61. Kimberlin DW et al. Red Book (2015): 2015 Report of the Committee on Infectious Diseases. – American academy of pediatrics, 2015; Mumps, Rubella, and Varicella Vaccine. Vaccine Safety. Center for Disease Control and Prevention: https://www.cdc.gov/vaccinesafety/vaccines/mmrv-vaccine.html
62. BSACI Recommendations for Combined Measles, Mumps and Rubella (MMR) Vaccination in Egg-Allergic children 2007; Gilbert T et al. Vaccination in egg-allergic individuals – A local guideline 2017. Hong Kong Institute Allergy 2017; 10: 24–9.
63. DiMiceli L et al. Vaccination of yeast sensitive individuals: review of safety data in the US vaccine adverse event reporting system (VAERS). Vaccine 2006; 24 (6): 703–7.
64. GlaxoSmithKline. ENGERIX-B Package Insert. Mississauga, Ontario, Canada. 2013. Also, http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM224503.pdf
65. Merck & Co. I. RECOMBIVAX HB Package Insert. Merck, Inc. Kenilworth, NJ USA. 2014.Also, https://www.merck.com/product/usa/pi_circulars/r/recombivax_hb/recombivax_pi.pdf66. Merck & Co. I. GARDASIL Package Insert. Merck, Inc. Kenilworth, NJ USA. 2011. Also,http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM111263.pdf
67. Stone Jr CA et al. Immediate Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized. J Allergy Clin Immunol: In Practice 2018.
68. Badiu I et al. Hypersensitivity reaction to human papillomavirus vaccine due to polysorbate 80. BMJ case reports 2012; 2012.
69. Wattanakrai P, Rajatanavin N. Thimerosal allergy and clinical relevance in Thailand. J Med Assoc Thailand 2007; 90 (9): 1775.
70. Lee-Wong M, Resnick D, Chong K. A generalized reaction to thimerosal from an influenza vaccine. Ann Allergy, Asthma Immunol 2005; 94 (1): 90–4.
71. King K, Paterson M, Green SK. Global justice and the proposed ban on thimerosal-containing vaccines. Pediatrics 2013; 131 (1): 154–6.
72. https://www.sovigripp.ru/sovigripp
73. https://www.rlsnet.ru/tn_index_id_3810.htm
74. https://www.rlsnet.ru/tn_index_id_5768.htm
75. https://www.rlsnet.ru/tn_index_id_5759.htm
76. http://allergen.org/search.php?Species=Hevea%20brasiliensis
77. Russell M et al. Vaccination of persons allergic to latex: a review of safety data in the Vaccine Adverse Event Reporting System (VAERS). Vaccine 2004; 23 (5): 664–7.
78. Kelso JM et al. Adverse reactions to vaccines. Ann Allergy, Asthma Immunol 2009; 103 (4): S1–S14.
Авторы
А.В. Максимова*1, Ю.С. Смолкин2
1 ООО «Научно-клинический консультативный центр аллергологии и иммунологии», Москва, Россия;
2 ФГБУ «Государственный научный центр "Институт иммунологии"» ФМБА России, Москва, Россия
*minaeva.a.v@mail.ru
1 Scientific Clinical Center of Allergology and Immunology, Moscow, Russia;
2 National Research Center – Institute of Immunology, Moscow, Russia
*minaeva.a.v@mail.ru
1 ООО «Научно-клинический консультативный центр аллергологии и иммунологии», Москва, Россия;
2 ФГБУ «Государственный научный центр "Институт иммунологии"» ФМБА России, Москва, Россия
*minaeva.a.v@mail.ru
________________________________________________
1 Scientific Clinical Center of Allergology and Immunology, Moscow, Russia;
2 National Research Center – Institute of Immunology, Moscow, Russia
*minaeva.a.v@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.